News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

Laura Rutter

Laura Rutter is a SM manager, analytical services at GlaxoSmithKline

Articles by Laura Rutter

EMA Guideline on Setting Health-Based Exposure Limits

ByAndrew Teasdale,Laura Rutter,Courtney M. Callis,Bruce D. Naumann,Gretchen Allison,Wendy Luo,Bryan K. Shipp,Christopher Seaman

December 2nd 2015

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.

Implementation of ICH Q3D Elemental Impurities Guideline: Challenges and Opportunities

BySarah Thompson,Nancy Lewen,Graham Cook,Andrew Teasdale,Katherine Ulman,Lance Smallshaw,Carlos W. Lee,Helmut Rockstroh,John Glennon,Samuel Powell,Cyrille C. Chéry,Laura Rutter,Laurence Harris,Vicki Woodward

March 2nd 2015

Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.

Latest Updated Articles

Implementation of ICH Q3D Elemental Impurities Guideline: Challenges and Opportunities
Published: March 2nd 2015 | Updated:
EMA Guideline on Setting Health-Based Exposure Limits
Published: December 2nd 2015 | Updated:

Trending on Pharmaceutical Technology

How Therapeutic and Analytical Advancements Help Drug Substance Testing Evolve

Shifting from Trial-and-Error to Rational Design Drives Efficiency in Pharmaceutical Formulation

© 2025 MJH Life Sciences^®

All rights reserved.